MOTS-c vs Cerebrolysin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.
Full details →Side-by-Side Comparison
| Aspect | MOTS-c | Cerebrolysin |
|---|---|---|
| Mechanism | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. | Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties. |
| Typical Dosage | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. | Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days. |
| Administration | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. | Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes. |
| Side Effects | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. | Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion. |
| Best For |